Oscient reiterated by JMP at market outperform

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities analyst Adam Cutler at a market outperform rating after the company pre-announced fourth-quarter top-line results with revenue of $9.2 million, about $8 million of which was attributed to antibiotic Factive sales. The results exceeded JMP's $8.1 million revenue estimate and consensus of $8.3 million. Factive scripts have been strong and should continue to increase into the first quarter, JMP said. There are multiple catalysts for this stock in 2006, the analyst said. Shares of the Waltham, Mass., pharmaceutical company were up 7 cents, or 2.58%, at $2.78 on volume of 1,167,294 shares versus the three-month running average of 479,032 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.